|Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting
|Tipo di pubblicazione
|Articolo su Rivista peer-reviewed
|Anno di Pubblicazione
|Villani, Maria Elena, Morea V., Consalvi V., Chiaraluce R., Desiderio Angiola, Benvenuto Eugenio, and Donini Marcello
|Amino Acid Sequence, amino acid substitution, Animals, Antibodies, Antibody, Antibody Affinity, antibody specificity, antigen binding, Antigens, article, Bacteria (microorganisms), binding affinity, Binding Sites, controlled study, Eukaryota, human, Humans, Immunoglobulin Fragments, immunoglobulin variable region, Mice, Molecular Sequence Data, Murinae, mutation, phenylalanine, priority journal, Prokaryota, protein domain, protein engineering, protein expression, protein stability, Sequence Alignment, serum, single chain fragment variable antibody, Site directed mutagenesis, thermodynamics, thermostability, tyrosine
The murine single-chain variable fragment F8 (scFv(F8)) is endowed with high intrinsic thermodynamic stability and can be functionally expressed in the reducing environment of both prokaryotic and eukaryotic cytoplasm. The stability and intracellular functionality of this molecule can be ascribed mostly to its framework regions and are essentially independent of the specific sequence and structure of the supported antigen-binding site. Therefore, the scFv(F8) represents a suitable scaffold to construct stable scFv chimeric molecules against different antigens by in vitro evolution or antigen-binding site grafting. Thanks to the favourable pharmacokinetic properties associated to a high thermodynamic stability of antibody fragments, such scFv(F8) variants may be exploited for a wide range of biomedical applications, from in vivo diagnosis to therapy, as well as to interfere with the function of intracellular proteins and pathogens, and for functional genomics studies. However, the potential immunogenicity of the murine framework regions represents a limitation for their exploitation in therapeutic applications. To overcome this limitation, we humanized a derivative of the scFv(F8), the anti-lysozyme scFv(11E), which is endowed with even higher thermodynamic stability than the parent antibody. The humanization was carried out by substituting the framework residues differing from closely related VH and VL domains of human origin with their human counterparts. Site-directed mutagenesis generated the fully humanized product and four intermediate scFvs, which were analyzed for protein expression and antigen binding. We found that the substitution Tyr 90 → Phe in the VH domain dramatically reduced the bacterial expression of all mutants. The back-mutation of Phe H90 to Tyr led to the final humanized variant named scFv(H5)H90Tyr. This molecule comprises humanized VH and VL framework regions and is endowed with HEL-binding affinity, stability in human serum and functionality under reducing conditions comparable to the murine cognate antibody. Consequently, the humanized scFv(H5)H90Tyr represents a suitable scaffold onto which new specificities towards antigens of therapeutic interest can be engineered for biomedical applications. © 2008 Elsevier Ltd. All rights reserved.
cited By 8